- Delayed-Onset Perforating Phenomenon in a Patient with Sorafenib-Induced Psoriasiform Eruption
-
Song CH, Song SY, Kim JE, Ro YS, Ko JY
- KMID: 2536330
- Korean J Dermatol.
- 2022 Nov;60(9):628-630.
Sorafenib is an inhibitor of receptor tyrosine kinases and the rat sarcoma/mitogen-activated protein kinase (RAS/MAPK) pathway that is approved for the treatment of patients with metastatic hepatocellular carcinoma (HCC) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparing efficacies of different treatment regimens in patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus using network meta-analysis
-
Lee S, Song SK, Bae B, Park Y
- KMID: 2534851
- Ann Surg Treat Res.
- 2022 Nov;103(5):280-289.
- doi: 10.4174/astr.2022.103.5.280
Purpose: Although various treatment regimens have been introduced for hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis (PVTT), comprehensive and direct comparisons between them are limited. Thus, the purpose... -
- CITED
-
- Close
- SHARE
-
- Close
- Atorvastatin inhibits the proliferation of MKN45-derived gastric cancer stem cells in a mevalonate pathway-independent manner
-
Choi YS, Cho HJ, Jung HJ
- KMID: 2532766
- Korean J Physiol Pharmacol.
- 2022 Sep;26(5):367-375.
- doi: 10.4196/kjpp.2022.26.5.367
Gastric cancer stem cells (GCSCs) are a major cause of radioresistance and chemoresistance in gastric cancer (GC). Therefore, targeting GCSCs is regarded as a powerful strategy for the effective treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria
-
Cho Y, Kim BH, Kim TH, Koh YH, Park JW
- KMID: 2528298
- J Liver Cancer.
- 2022 Mar;22(1):63-68.
- doi: 10.17998/jlc.2022.01.18
The prognosis of patients with advanced hepatocellular carcinoma (HCC) with tumor thrombus extending to the inferior vena cava (IVC) is extremely poor. Herein, we present a rare case of advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
-
Kim MJ, Baek HS, Lee SH, Lim DJ
- KMID: 2522923
- Int J Thyroidol.
- 2021 Nov;14(2):175-179.
- doi: 10.11106/ijt.2021.14.2.175
Sorafenib, an oral multi-target tyrosine kinase inhibitor (MTKI) for treatment of radioiodine-refractory differentiated thyroid cancer can induce acute or chronic pancreatitis as an adverse event. However, there have been no... -
- CITED
-
- Close
- SHARE
-
- Close
- Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
-
Trillsch F, Mahner S, Czogalla B, Rottmann M, Chekerov R, Braicu EI, Oskay-Öczelik G, Wimberger P, Richter R, Sehouli J
- KMID: 2526394
- J Gynecol Oncol.
- 2021 May;32(3):e37.
- doi: 10.3802/jgo.2021.32.e37
Objective: Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
-
Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS
- KMID: 2513701
- Gut Liver.
- 2021 Mar;15(2):284-294.
- doi: 10.5009/gnl19367
Background/Aims: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis
-
Jo HH, Chun SJ, Yoo JJ, Lee MH, Kim SG, Kim YS
- KMID: 2508031
- J Liver Cancer.
- 2020 Sep;20(2):177-182.
- doi: 10.17998/jlc.20.2.177
JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and... -
- CITED
-
- Close
- SHARE
-
- Close
- Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
-
Goh MJ, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2508028
- J Liver Cancer.
- 2020 Sep;20(2):160-166.
- doi: 10.17998/jlc.20.2.160
Transarterial radioembolization (TARE) with yttrium-90 microspheres has become widely utilized in managing hepatocellular carcinoma (HCC). The utility of TARE is expanding with new insights through experiences from real-world practice and... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
-
Han S, Kim DY
- KMID: 2504503
- Clin Mol Hepatol.
- 2020 Jul;26(3):305-308.
- doi: 10.3350/cmh.2020.0096
-
- CITED
-
- Close
- SHARE
-
- Close
- Switching to systemic therapy after locoregionaltreatment failure: Definition and best timing
-
Ogasawara , Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi , Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N
- KMID: 2500378
- Clin Mol Hepatol.
- 2020 Apr;26(2):155-162.
- doi: 10.3350/cmh.2019.0021n
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
-
Lee SK, Jang JW, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK
- KMID: 2505847
- J Liver Cancer.
- 2020 Mar;20(1):84-89.
- doi: 10.17998/jlc.20.1.84
The efficacy and safety of sequential systemic therapy for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) are not well established. This study describes a successful experience... -
- CITED
-
- Close
- SHARE
-
- Close
- Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
-
Kim J, Chang JW, Park JY
- KMID: 2505845
- J Liver Cancer.
- 2020 Mar;20(1):72-77.
- doi: 10.17998/jlc.20.1.72
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line... -
- CITED
-
- Close
- SHARE
-
- Close
- Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
-
Lim DH, Yoon JH, Jun DW, Lee OY, Yoon BC, Lee HR, Kim KS, Choi HS
- KMID: 2505844
- J Liver Cancer.
- 2020 Mar;20(1):67-71.
- doi: 10.17998/jlc.20.1.67
Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its... -
- CITED
-
- Close
- SHARE
-
- Close
- Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
-
Makol A, Kaur H, Sharma S, Kanthaje S, Kaur R, Chakraborti A
- KMID: 2501315
- Clin Mol Hepatol.
- 2020 Jan;26(1):45-53.
- doi: 10.3350/cmh.2019.0031
Background/Aims: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event
-
Kim DH, Kim M, Yim HJ, Suh SJ, Jung YK
- KMID: 2463617
- J Liver Cancer.
- 2019 Sep;19(2):154-158.
- doi: 10.17998/jlc.19.2.154
A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma
-
Kim J, Yoo GS, Sinn DH, Park HC, Koh KC
- KMID: 2463614
- J Liver Cancer.
- 2019 Sep;19(2):136-142.
- doi: 10.17998/jlc.19.2.136
Proton beam therapy (PBT) is one of the advances in radiotherapy techniques, which enables dose escalation with lower probability of radiation-induced liver or gastrointestinal injuries. However, the chest wall proximal... -
- CITED
-
- Close
- SHARE
-
- Close
- An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era
-
Lee CU, Lee YS, Kim JH, Lee M, Kim S, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS
- KMID: 2463612
- J Liver Cancer.
- 2019 Sep;19(2):117-127.
- doi: 10.17998/jlc.19.2.117
BACKGROUND/AIMS: Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the prognosis predictors and the role of second-line cytotoxic systemic chemotherapy (CSC) in... -
- CITED
-
- Close
- SHARE
-
- Close
- The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma
-
Yim SY, Lee JS
- KMID: 2463610
- J Liver Cancer.
- 2019 Sep;19(2):97-107.
- doi: 10.17998/jlc.19.2.97
The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification... -
- CITED
-
- Close
- SHARE
-
- Close
- Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
-
Kim BH, Park JW, Kim JS, Lee SK, Hong EK
- KMID: 2448374
- Gut Liver.
- 2019 May;13(3):342-348.
- doi: 10.5009/gnl18345
BACKGROUND/AIMS: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
